Fig. 7

G6PD is inversely correlated to DFS in breast cancer patients. a, b Scatter plot presenting the normalized gene expression of G6PD within breast cancer subtypes. Significance was tested comparing the expression in Her2+ population with other subtypes. Results highlight that the expression of G6PD is significantly higher in the Her2+ population supporting the use of a G6PD inhibitor for this group of patients. c, d Scatter plot representing the normalized gene expression of G6PD in patients with disease-free survival (DFS) and patients with disease recurrence. Significant differences in the expression of G6PD is shown in the Metabric and Pawitan dataset. Both show a higher expression of G6PD in patients with disease recurrence compared to patients without disease recurrence. Note: The analysis was performed using all sample population based on the reduced numbers of Her2+ patients and the number of recurring and non-recurring patients within this selection. e, f Kaplan-Meier analysis on DFS after a median split. Equal number of patients were in both groups. Significant differences in DFS are shown in the Metabric and Pawitan dataset. Both show that an increased expression of G6PD results in an earlier time of relapse. Note: The difference in the graphs of Metabric and Pawitan are based on the shorter length of follow-up of Pawitan compared to Metabric. The analysis was performed using all sample population based on the reduced numbers of Her2+ patients and the number of recurring and non-recurring patients within this selection